Options markets reflect moderate implied volatility, suggesting investor anticipation ahead of the next earnings call. All of this should help Pfizer gain momentum and potentially enter a new phase of growth within the next few years as cost savings kick in and new products start boosting revenue. Pfizer recently said it expects more than $7 billion in cost savings by 2027, and the company has said non-coronavirus new launches should generate $20 billion in sales in 2030. While the stock has risen 15% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us. Pfizer stock price climbed to $28.55 early today on above-average pre-market volume. Traders are monitoring $28.80 as an intraday breakout trigger aligned with sector momentum patterns.